A New Breakthrough for augmentation of neurological recovery following stroke
The INR has made a stunning discovery: that the neurological status of patients following stroke, even years after the acute event, may rapidly improve following the use of the INR’s patented local anti-TNF treatment (see Edward Tobinick MD, Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011 Feb;25(2):145-155.). These published results, and the subsequent clinical experience of INR physicians, suggest that excess TNF plays an important role in post-stroke chronic disability and establish the promise that the INR’s patented anti-TNF treatment presents for stroke recovery and stroke rehabilitation. Results can vary, and more than one dose may be necessary for optimal benefit, but these results represent a new breakthrough in the understanding of the neurological basis of chronic brain dysfunction following stroke. Please see strokebreakthrough.com for further detailed information.
We encourage stroke patients to consult with the INR following hospital discharge, even years or decades after the stroke has occurred.
1. Martin-Villalba A, Hahne M, Kleber S et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ, 8(7), 679-686 (2001).
2. Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand, 104(5), 288-295 (2001).
3. Alexandrova ML, Bochev PG. Oxidative stress during the chronic phase after stroke. Free Radic Biol Med, 39(3), 297-316 (2005).
4. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother, 10(6), 985-1002 (2010).
5. Zaremba J, Skrobanski P, Losy J. Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed Pharmacother, 55(5), 258-263 (2001).
6. Marousi S, Ellul J, Karakantza M. Genetic polymorphisms of type-1 and type-2 inflammatory cytokines in ischaemic stroke. Vascular Disease Prevention, 5(2), 89-103 (2008).